• No results found

C III

Apolipoprotein C III(Lys58    Glu)  Identification of an apolipoprotein C III variant in a family with hyperalphalipoproteinemia

Apolipoprotein C III(Lys58 Glu) Identification of an apolipoprotein C III variant in a family with hyperalphalipoproteinemia

... Apolipoprotein C-III is a major protein constituent of triglyceride rich lipoproteins and ...Apo C-III putatively inhibits lipolysis and the apo E mediated hepatic uptake of remnants from ...

9

Association of apolipoproteins C-I, C-II, C-III and E with coagulation markers and venous thromboembolism risk

<p>Association of apolipoproteins C-I, C-II, C-III and E with coagulation markers and venous thromboembolism risk</p>

... randomly selected from a large population-based study, the MEGA study, but was not large enough for strong conclusions on the association with VTE risk. Second, we cannot rule out that some associations between apos and ...

9

An abnormal triglyceride rich lipoprotein containing excess sialylated apolipoprotein C III

An abnormal triglyceride rich lipoprotein containing excess sialylated apolipoprotein C III

... apo C-III-2 band with a corresponding increase in the region of apo C-III-0, which suggests that the increased content of apo C-III-2 in the abnormal is due to excessive ...

9

The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism

The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism

... apolipoprotein C-III; apoE: apolipoprotein E; ASO: Antisense oligonucleotide; CKD: Chronic kidney disease; CM: Chylomicron; CVD: Cardiovascular disease; DAG: Diacylglycerol; EC: Endothelial cell; FCS: ...

7

Modulation of lipoprotein lipase activity by apolipoproteins  Effect of apolipoprotein C III

Modulation of lipoprotein lipase activity by apolipoproteins Effect of apolipoprotein C III

... From a total of 22 hypertriglyceridemic subjects tested, 14 subjects were selected on the basis of normal postheparin plasma lipoprotein lipase (LPL) levels and the presence of LPL inhibitory activity in their fasting ...

8

Retinoids increase human apo C III expression at the transcriptional level via the retinoid X receptor  Contribution to the hypertriglyceridemic action of retinoids

Retinoids increase human apo C III expression at the transcriptional level via the retinoid X receptor Contribution to the hypertriglyceridemic action of retinoids

... apo C-III to the list of genes involved in lipoprotein metabolism, whose expression is con- trolled by ...apo C-III gene promoter transcription via the C3P ...

9

Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials

Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials

... This study was designed according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. 25 PubMed-Medline, Scopus and ISI Web of Knowledge databases were searched using ...

9

Apolipoprotein C III 1 activates lysosomal sphingomyelinase in vitro

Apolipoprotein C III 1 activates lysosomal sphingomyelinase in vitro

... Apolipoprotein (apo)C-III-1 from human very low density lipoprotein stimulates 14-fold the activity of lysosomal sphingomyelinase from human fibroblasts. At the sphingomyelin concentrations tested, maximal ...

6

Apolipoprotein A-I, A-II, B, C-II, and C-III in Children with Insulin-dependent Diabetes Mellitus

Apolipoprotein A-I, A-II, B, C-II, and C-III in Children with Insulin-dependent Diabetes Mellitus

... IDDM children aged 4 to 1 2 years were selected for this study and were classified into three groups of diabetic control (good, fair, and poor), according to their glucose, HbAlc, and fr[r] ...

8

Deoxyribonucleic acid polymorphism in the apolipoprotein A 1 C III gene cluster  Association with hypertriglyceridemia

Deoxyribonucleic acid polymorphism in the apolipoprotein A 1 C III gene cluster Association with hypertriglyceridemia

... This report demonstrates that the DNA polymorphism originally described in the 3' flanking region of the A-I gene is located within the gene for apo C-Ill, and furthermore that it may pr[r] ...

7

Regulation of the Production of Infectious Genotype 1a Hepatitis C Virus by NS5A Domain III

Regulation of the Production of Infectious Genotype 1a Hepatitis C Virus by NS5A Domain III

... the C-terminal region of JFH-1/H77S se- quence identity described above ...domain III by the NetPhos ...domain III of H77S caused only a modest decrease in infectious virus yield ...

12

Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study

Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study

... analysis, TGs were included in an additional model (Model 4) as a covariate due to the known biological ef- fect of apoC-III on TG metabolism [10] i.e., we exam- ined the impact of TGs as an intermediate effector ...

8

Rhodium(III)-Catalyzed C-H Activation/Annulation with Vinyl Esters as an Acetylene Equivalent

Rhodium(III)-Catalyzed C-H Activation/Annulation with Vinyl Esters as an Acetylene Equivalent

... 4j, C-H activation occurred at the less-hindered position para- rather than meta- to the phenyl/N-Boc substituent, giving 5i and 5j as single ...rhodium-mediated C-H activation has been noted previous- ly ...

5

Chlamydial Protease Like Activity Factor and Type III Secreted Effectors Cooperate in Inhibition of p65 Nuclear Translocation

Chlamydial Protease Like Activity Factor and Type III Secreted Effectors Cooperate in Inhibition of p65 Nuclear Translocation

... CPAF complementation of null mutant strain restores p65 nuclear translocation inhibition. In order to confirm the host and chlamydial phenotypes associated with the CPAF gene, the null strain was complemented with CPAF ...

9

Organometallic iridium(III) cyclopentadienyl anticancer complexes containing C,N chelating ligands

Organometallic iridium(III) cyclopentadienyl anticancer complexes containing C,N chelating ligands

... All the C,N- complexes showed very promising anticancer activity toward A2780 human ovarian cancer cells. The Cp* complexes possess activity comparable to cisplatin. The introduction of phenyl or biphenyl ...

30

Structure of HrcQ(B)-C, a conserved component of the bacterial type III secretion systems

Structure of HrcQ(B)-C, a conserved component of the bacterial type III secretion systems

... approximate dimensions of 25 ⫻ 30 ⫻ 90 Å 3 . The four monomers assemble into two tightly bound homodimers that are packed together to form a dimer of dimers. The dimers associate with each other in such a way that the ...

7

Tuning the Reactivity of Terminal Nickel(III)?Oxygen Adducts for C?H Bond Activation

Tuning the Reactivity of Terminal Nickel(III)?Oxygen Adducts for C?H Bond Activation

... a C–H bond, the ΔG° is equal to the difference between the bond dissociation free energy ( BDFE ) of the C–H bond that is broken in the substrate and that of the O–H bond that is ...stronger C–H ...

9

I Believe Student Samples

I Believe Student Samples

... I love being given first chair parts now and then, and even just second chair parts that have the main melody.. Yet I find myself also discovering a deep appreciation for the way my ha[r] ...

6

An unprecedented family of luminescent iridium(III) complexes bearing a six membered chelated tridentate C^N^C ligand

An unprecedented family of luminescent iridium(III) complexes bearing a six membered chelated tridentate C^N^C ligand

... where C^N^C is a bis(six-membered) chelating tridentate tripod ligand derived from 2-benzhydryl- pyridine (bnpy) and N^N is 4,4 ′ -di-tert-butyl-2,2 ′ -bipyridine (dtBubpy), is ...double C − H bond ...

7

Manufacturing Process Defects of Automotive Brake Drums and Implementation of Poka-Yoke – A Case Study

Manufacturing Process Defects of Automotive Brake Drums and Implementation of Poka-Yoke – A Case Study

... On the horizontal axis, the different defects are given using the abbreviations or nomenclature shown in Table: 2. On the vertical axis, the share of each defect is shown in percentage of the total defects found in ...

11

Show all 10000 documents...

Related subjects